[Malignant lymphoma].
A strategy for treatment of malignant lymphoma requires fundamentally a field of multidisciplinary treatment including mainly radiotherapy and chemotherapy in a collaboration with surgical procedure and immunotherapeutic maneuver. In the therapy of malignant lymphoma the classifications of both the histologic type and the stage of disease which influence therapeutic effect and prognosis are actually very important to decide a plan of treatment. In particular, recent advance of chemotherapy makes possible of curing of advanced lymphoma patients, especially Hodgkin's disease. In this article a cure-oriented therapy was discussed under some considerations of specificity of Japanese lymphoma.
Shirakawa
S
S
Tanaka
I
I
Kita
K
K
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001761:Bleomycin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D006689:Hodgkin Disease / Q000188:drug therapy / Q000532:radiotherapy; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy / Q000628:therapy*; D008297:Male; D008466:Mechlorethamine / Q000008:administration & dosage; D009367:Neoplasm Staging; D011241:Prednisone / Q000008:administration & dosage; D011344:Procarbazine / Q000008:administration & dosage; D011379:Prognosis; D014750:Vincristine / Q000008:administration & dosage
D001761:Bleomycin; D011344:Procarbazine; D008466:Mechlorethamine; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone